These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 26199205)

  • 1. A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers.
    Kamada Y; Ono M; Hyogo H; Fujii H; Sumida Y; Mori K; Tanaka S; Yamada M; Akita M; Mizutani K; Fujii H; Yamamoto A; Takamatsu S; Yoshida Y; Itoh Y; Kawada N; Chayama K; Saibara T; Takehara T; Miyoshi E
    Hepatology; 2015 Nov; 62(5):1433-43. PubMed ID: 26199205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Mac-2 binding protein levels as a novel diagnostic biomarker for prediction of disease severity and nonalcoholic steatohepatitis.
    Kamada Y; Fujii H; Fujii H; Sawai Y; Doi Y; Uozumi N; Mizutani K; Akita M; Sato M; Kida S; Kinoshita N; Maruyama N; Yakushijin T; Miyazaki M; Ezaki H; Hiramatsu N; Yoshida Y; Kiso S; Imai Y; Kawada N; Takehara T; Miyoshi E
    Proteomics Clin Appl; 2013 Oct; 7(9-10):648-56. PubMed ID: 23775887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Fucosylated Haptoglobin as a Novel Diagnostic Biomarker for Predicting Hepatocyte Ballooning and Nonalcoholic Steatohepatitis.
    Kamada Y; Akita M; Takeda Y; Yamada S; Fujii H; Sawai Y; Doi Y; Asazawa H; Nakayama K; Mizutani K; Fujii H; Yakushijin T; Miyazaki M; Ezaki H; Hiramatsu N; Yoshida Y; Kiso S; Imai Y; Kawada N; Takehara T; Miyoshi E
    PLoS One; 2013; 8(6):e66328. PubMed ID: 23805214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis.
    Alkhouri N; Johnson C; Adams L; Kitajima S; Tsuruno C; Colpitts TL; Hatcho K; Lawitz E; Lopez R; Feldstein AE
    PLoS One; 2018; 13(8):e0202226. PubMed ID: 30161179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease.
    Ozturk O; Colak Y; Senates E; Yilmaz Y; Ulasoglu C; Doganay L; Ozkanli S; Oltulu YM; Coskunpinar E; Tuncer I
    World J Gastroenterol; 2015 Jul; 21(26):8096-102. PubMed ID: 26185381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Fucosylated Haptoglobin and Mac-2 Binding Protein as Serum Biomarkers to Estimate Liver Fibrosis in Patients with Chronic Hepatitis C.
    Tawara S; Tatsumi T; Iio S; Kobayashi I; Shigekawa M; Hikita H; Sakamori R; Hiramatsu N; Miyoshi E; Takehara T
    PLoS One; 2016; 11(3):e0151828. PubMed ID: 27002630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel model using mean platelet volume and neutrophil to lymphocyte ratio as a marker of nonalcoholic steatohepatitis in NAFLD patients: multicentric study.
    Abdel-Razik A; Mousa N; Shabana W; Refaey M; ElMahdy Y; Elhelaly R; Elzehery R; Zalata K; Arafa M; Elbaz S; Hafez M; Awad M
    Eur J Gastroenterol Hepatol; 2016 Jan; 28(1):e1-9. PubMed ID: 26469357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma Pentraxin 3 Differentiates Nonalcoholic Steatohepatitis (NASH) from Non-NASH.
    Boga S; Koksal AR; Alkim H; Yilmaz Ozguven MB; Bayram M; Ergun M; Sisman G; Tekin Neijmann S; Alkim C
    Metab Syndr Relat Disord; 2015 Nov; 13(9):393-9. PubMed ID: 26367098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
    Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
    Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The development of a clinical score for the prediction of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease using routine parameters.
    Chunming L; Jianhui S; Hongguang Z; Chunwu Q; Xiaoyun H; Lijun Y; Xuejun Y
    Turk J Gastroenterol; 2015 Sep; 26(5):408-16. PubMed ID: 26215061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonalcoholic fatty liver disease: biomarkers as diagnostic tools for liver damage assessment in adult patients from Argentina.
    Valva P; Rios D; Casciato P; Gadano A; Galdame O; Mullen E; Bertot G; de Matteo E; Preciado MV
    Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):637-644. PubMed ID: 29384795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Otgonsuren M; Estep MJ; Hossain N; Younossi E; Frost S; Henry L; Hunt S; Fang Y; Goodman Z; Younossi ZM
    J Gastroenterol Hepatol; 2014 Dec; 29(12):2006-13. PubMed ID: 25039333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Value of serum osteoprotegerin in noninvasive diagnosis of nonalcoholic steatohepatitis].
    Yang M; Liu Y; Zhou G; Guo X; Zou S; Liu S; Jiang L; Liu Y; Zhu L; Guo C; Zhao J
    Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):96-101. PubMed ID: 26983475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of Aspartate Aminotranferase and Tumor Necrosis Factor-α as Non Invasive Diagnostic Tools for Non Alcoholic Steatohepatitis (NASH).
    Purnomo HD; Mundhofir FE; Kasno ; Sudijanto E; Darmono ; Daldiyono ; Djokomoeljanto R; Faradz SM
    Acta Med Indones; 2015 Jan; 47(1):16-23. PubMed ID: 25948763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of Serum microRNAs -122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis.
    Becker PP; Rau M; Schmitt J; Malsch C; Hammer C; Bantel H; Müllhaupt B; Geier A
    PLoS One; 2015; 10(11):e0142661. PubMed ID: 26565986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development of a non-invasive model to predict the presence of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease.
    Goh GB; Issa D; Lopez R; Dasarathy S; Dasarathy J; Sargent R; Hawkins C; Pai RK; Yerian L; Khiyami A; Pagadala MR; Sourianarayanane A; Alkhouri N; McCullough AJ
    J Gastroenterol Hepatol; 2016 May; 31(5):995-1000. PubMed ID: 26589761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of novel noninvasive markers for diagnosing nonalcoholic steatohepatitis and related fibrosis by data mining.
    Yoshimura K; Okanoue T; Ebise H; Iwasaki T; Mizuno M; Shima T; Ichihara J; Yamazaki K
    Hepatology; 2016 Feb; 63(2):462-73. PubMed ID: 26390046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of Nonalcoholic Fatty Liver Disease Via a Novel Panel of Serum Adipokines.
    Jamali R; Arj A; Razavizade M; Aarabi MH
    Medicine (Baltimore); 2016 Feb; 95(5):e2630. PubMed ID: 26844476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bayesian approach to an integrated multimodal noninvasive diagnosis of definitive nonalcoholic steatohepatitis in the spectrum of nonalcoholic fatty liver disease.
    Yilmaz Y; Eren F
    Eur J Gastroenterol Hepatol; 2014 Nov; 26(11):1292-5. PubMed ID: 25171027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in non-alcoholic fatty liver disease.
    Lai LL; Chan WK; Sthaneshwar P; Nik Mustapha NR; Goh KL; Mahadeva S
    PLoS One; 2017; 12(4):e0174982. PubMed ID: 28369100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.